Respirable Dry Powder Formulations for Pulmonary Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pulmonary drug delivery methods, such as metered dose inhalers and nebulizers, face limitations in delivering high doses of active drug to the alveoli due to large quantities of inert carriers and solvents, which reduce drug purity and require multiple inhalations, and dry powder inhalers struggle with particle size, density, and dispersibility, leading to inefficient delivery.
Innovation Solution
Development of respirable dry powders comprising leucine, calcium lactate, and sodium chloride with a specific ion ratio, achieving high tap density and dispersibility, allowing for efficient delivery of therapeutic agents directly to the respiratory tract with minimal non-drug material, enabling effective treatment of respiratory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If metered dose inhalers use volatile liquid carriers to deliver therapeutic agents, then the drug can be delivered to the upper and middle airways, but the dose per actuation is limited and large quantities of inert carriers are required
Solution Approach 1:
The invention changes the physical state parameter of the drug formulation from liquid aerosol to dry powder, enabling higher drug loading concentrations. By formulating as respirable dry particles with controlled size distribution (0.5-5 microns), the system achieves efficient pulmonary delivery with significantly reduced inert carrier requirements compared to liquid aerosol systems
Solution Approach 2:
The invention uses composite dry powder formulations combining the therapeutic agent with minimal excipients optimized for pulmonary delivery. The composite structure enables high drug loading while maintaining respirability and dispersibility, eliminating the need for large quantities of inert liquid carriers required by MDI systems
2Volume of moving object
If dry powder inhalers use small respirable particles for alveolar delivery, then the drug can reach the alveoli, but the particles are harder to disperse in air
Solution Approach 1:
The invention applies local quality by creating particles with specific surface characteristics and size distribution optimized for both respirability and dispersibility. The dry powder formulation incorporates surface-modified particles with controlled morphology that reduce interparticle adhesion while maintaining small size (0.5-5 microns) for alveolar penetration
Solution Approach 2:
The invention changes physical parameters including particle size distribution, density, and surface properties to achieve optimal balance between respirability and dispersibility. By controlling these parameters, the formulation enables small particles to be effectively dispersed in air during inhalation while maintaining their ability to reach the alveoli
3Volume of moving object
If liquid aerosol nebulizers are used to create respirable droplets, then the droplets can be delivered to the respiratory tract, but the droplet size is non-uniform and requires impaction onto baffles
Solution Approach 1:
The invention replaces the complex mechanical nebulization system with a simpler dry powder aerosolization system. By using compressed air or patient inhalation flow to directly aerosolize the dry powder formulation, the system eliminates the need for liquid aerosol generation, baffle impaction, and associated size uniformity problems
Solution Approach 2:
The invention changes the physical state from liquid aerosol to dry powder aerosol, fundamentally altering the size distribution characteristics. The dry powder formulation naturally produces a narrower size distribution (0.5-5 microns) upon aerosolization compared to liquid nebulizers, eliminating the need for secondary impaction processes
4Ease of operation
If dry powder formulations use lactose blending to enable dosing of small particles, then the particles can be inhaled, but the process is inefficient and does not work for some drugs
Solution Approach 1:
The invention extracts and eliminates lactose and other inert blending carriers from the formulation. By developing self-dispersing dry powder formulations with optimized particle properties, the system achieves inhalability without requiring lactose blending, thereby improving dosing efficiency and expanding applicability to drugs incompatible with lactose
Solution Approach 2:
The invention changes the particle properties including surface characteristics, morphology, and interparticle forces to enable self-dispersion without lactose carriers. This parameter optimization allows efficient dosing of small respirable particles while eliminating the inefficiencies and limitations of lactone blending processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The respirable dry powders provide superior efficacy by delivering high concentrations of active drug directly to the alveoli with improved dispersibility and density, enhancing treatment outcomes for respiratory diseases such as asthma and COPD with reduced side effects and increased patient convenience.
Implementation Method 1
spray drying the feedstock to produce the dry particles
Implementation Method 2
disperses the respirable dry particles to be inhaled in air
Data Source
Figure 1A
Figure 1A
Figure 1B
AI summary
The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.